Light-Activated Peptide Snaps Cancer Drugs onto Antibodies at a Precise Location
A photoreactive peptide that binds antibody Fc regions enables site-specific attachment of exactly two drug molecules to trastuzumab using light and click chemistry.
Quick Facts
What This Study Found
A photoreactive Fc-binding peptide achieved site-specific conjugation to trastuzumab at Glu-382, enabling precise DAR 2 antibody-drug conjugate formation via click chemistry.
Key Numbers
Site-specific at Glu-382; DAR 2; photoreactive Fc-binding peptide; click chemistry drug attachment
How They Did This
Peptide chemistry and bioconjugation: designed high-affinity IgG Fc-binding peptide with photoreactive amino acid, UV-activated conjugation to trastuzumab, then click chemistry for drug attachment. Product characterized for DAR.
Why This Research Matters
Current ADCs attach drugs randomly to antibodies, creating inconsistent products. Site-specific conjugation improves manufacturing reproducibility, drug-to-antibody ratio control, and potentially efficacy.
The Bigger Picture
ADCs are one of the fastest-growing cancer drug classes (B+ market). Better conjugation chemistry means more uniform products, simpler manufacturing, and potentially improved patient outcomes.
What This Study Doesn't Tell Us
Chemistry proof-of-concept only — no cell killing or in vivo efficacy data; only tested on trastuzumab; scalability of photoconjugation not assessed.
Questions This Raises
- ?Does site-specific DAR 2 conjugation improve anti-tumor efficacy compared to random conjugation ADCs?
- ?Can this approach work with other therapeutic antibodies beyond trastuzumab?
- ?Is UV-activated conjugation practical at manufacturing scale?
Trust & Context
- Key Stat:
- DAR 2 achieved Exactly 2 drugs per antibody via site-specific photoconjugation at Glu-382
- Evidence Grade:
- Preliminary — chemistry proof-of-concept without biological activity data.
- Study Age:
- Published in 2020; ADC technology and site-specific conjugation methods have continued to advance rapidly.
- Original Title:
- Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation.
- Published In:
- Organic letters, 22(21), 8419-8423 (2020)
- Authors:
- Lee, TaeJin, Kim, Ju Hwan(2), Kwon, Se Jeong, Park, Sun Hee, Kim, Jinyoung, Kang, Hyo Jin, Chung, Sang J
- Database ID:
- RPEP-04937
Evidence Hierarchy
Frequently Asked Questions
What is an antibody-drug conjugate?
A targeted cancer therapy that attaches a toxic drug to an antibody so the drug is delivered specifically to cancer cells, reducing side effects.
Why does it matter where the drug attaches?
Random attachment creates a mix of products — some with too many drugs (toxic), some with too few (ineffective). Precise attachment at one specific site creates a uniform, predictable product.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04937APA
Lee, TaeJin; Kim, Ju Hwan; Kwon, Se Jeong; Park, Sun Hee; Kim, Jinyoung; Kang, Hyo Jin; Chung, Sang J. (2020). Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation.. Organic letters, 22(21), 8419-8423. https://doi.org/10.1021/acs.orglett.0c03049
MLA
Lee, TaeJin, et al. "Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation.." Organic letters, 2020. https://doi.org/10.1021/acs.orglett.0c03049
RethinkPeptides
RethinkPeptides Research Database. "Photoconjugation of an Fc-Specific Peptide Enables Efficient..." RPEP-04937. Retrieved from https://rethinkpeptides.com/research/lee-2020-photoconjugation-of-an-fcspecific
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.